Premium
Indolo‐Phakellins as β5‐Specific Noncovalent Proteasome Inhibitors
Author(s) -
Beck Philipp,
Lansdell Theresa A.,
Hewlett Nicole M.,
Tepe Jetze J.,
Groll Michael
Publication year - 2015
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201410168
Subject(s) - proteasome , natural product , chemistry , drug discovery , non covalent interactions , stereochemistry , biochemistry , computational biology , pharmacology , biology , molecule , hydrogen bond , organic chemistry
The proteasome represents an invaluable target for the treatment of cancer and autoimmune disorders. The application of proteasome inhibitors, however, remains limited to blood cancers because their reactive headgroups and peptidic scaffolds convey unfavorable pharmacodynamic properties. Thus, the discovery of more drug‐like lead structures is indispensable. In this study, we present the first structure of the proteasome in complex with an indolo‐phakellin that exhibits a unique noncovalent binding mode unparalleled by all hitherto reported inhibitors. The natural product inspired pentacyclic alkaloid binds solely and specificially into the spacious S3 subpocket of the proteasomal β5 substrate binding channel, gaining major stabilization through halogen bonding with the protein backbone. The presented compound provides an ideal scaffold for the structure‐based design of subunit‐specific nonpeptidic proteasome‐blockers.